Brendan M Everett1, Robert J Smith, William R Hiatt. 1. From Harvard Medical School and Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital - both in Boston (B.M.E.); the Department of Medicine, Alpert Medical School, and the Department of Health Services, Policy, and Practice, School of Public Health, Brown University; and Ocean State Research Institute, Providence VA Medical Center - all in Providence, RI (R.J.S.); and the Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, and CPC Clinical Research - both in Aurora (W.R.H.). All three authors participated as voting members of the FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting on alirocumab, and Drs. Smith and Hiatt participated as voting members of the Advisory Committee meeting on evolocumab.
Authors: Gregory P Hess; Pradeep Natarajan; Kamil F Faridi; Anna Fievitz; Linda Valsdottir; Robert W Yeh Journal: Circulation Date: 2017-10-30 Impact factor: 29.690
Authors: Carmen Lammi; Jacopo Sgrignani; Gabriella Roda; Anna Arnoldi; Giovanni Grazioso Journal: ACS Med Chem Lett Date: 2018-12-03 Impact factor: 4.345
Authors: Peter Yan; Eng Kiat Kevin Tan; Jason Chon Jun Choo; Choon Fong Stanley Liew; Titus Lau; David D Waters Journal: Singapore Med J Date: 2016-07 Impact factor: 1.858